GC Cell Launches Cell and Gene Therapy Alliance with Four Bio Companies

Excell Therapeutics, Corestem ChemOn, GenMedicine, and GCCL Join Alliance
Establishing End-to-End Support System from Development to GMP Manufacturing and Clinical Analysis
Expanding Korea's Cell and Gene Therapy Collaborative Ecosystem Expected

GC Cell has established a collaborative system together with Excell Therapeutics, Corestem ChemOn, GenMedicine, and GCCL to support the entire cycle of cell and gene therapy (CGT) development. The plan is to link the specialized capabilities of each participating company to support new drug development and commercialization by domestic bio companies while enhancing global competitiveness.

On July 8, GC Cell announced that it had signed a "CGT Value Chain Alliance" memorandum of understanding (MOU) with Excell Therapeutics, Corestem ChemOn, GenMedicine, and GCCL to create a collaborative ecosystem for the cell and gene therapy (CGT) industry.

Officials from GC Cell are taking a commemorative photo at the alliance ceremony marking the launch of the cell and gene therapy collaboration with the four major domestic bio companies. GC Cell

This agreement was established so that companies with expertise in the core areas required for cell and gene therapy development can build a collaborative system to shorten the development and commercialization timelines for domestic bio companies and enhance global competitiveness.

The alliance includes GC Cell, Excell Therapeutics, Corestem ChemOn, GenMedicine, and GCCL. GC Cell is responsible for CGT contract development and manufacturing (CDMO), GMP manufacturing, regulatory affairs (RA), and manufacturing and quality management (CMC) consulting. Excell Therapeutics will provide cell culture media, Corestem ChemOn will oversee nonclinical and toxicity studies, GenMedicine will focus on viral vectors, and GCCL will be in charge of bioanalysis and central laboratory services for clinical trials.

Through this alliance, the participating companies plan to support the entire development cycle—including process development, nonclinical studies, vector production, clinical trial analysis, and GMP manufacturing—within a single collaborative framework. The company expects that this will improve development efficiency and the speed of commercialization, while also strengthening the foundation for domestic bio companies to enter global markets.

Won Sungyong, CEO of GC Cell, stated, "This alliance is highly significant in that it connects the core competencies of Korea's CGT industry into a single value chain. By collaborating with specialized companies in each field, we will help our clients pursue their businesses more efficiently from development to commercialization, and we will grow into a CGT collaboration platform with global competitiveness."

This content was produced with the assistance of AI translation services.